Trial ID 20363 | Maryland Oncology Hematology Trial ID 20363 – Maryland Oncology Hematology

Trial ID 20363

Trial Information - Phase III

SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

Disease Specifics: mHER2-

Protocol ID: D8532C00001

Sponsor: AstraZeneca plc

Status: OPEN TO ENROLLMENT

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Breast

Investigator

Ackerman MD, Courtney

Status

OPEN TO ENROLLMENT

Sponsor

AstraZeneca plc

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology